Allergan Fortifies Defenses In Response To Valeant’s Hostile Bid
This article was originally published in The Gray Sheet
Executive Summary
Allergan’s board adopted a so-called poison pill stockholder rights plan to hold off Valeant’s hostile takeover effort while it reviews the unsolicited offer.
You may also be interested in...
Allergan To Sell Lap-Band Franchise To Apollo For Up To $110 Million
The firm announced Oct. 29 an agreement with Apollo Endosurgery to sell its obesity intervention business, including the Lap-Band adjustable band.
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.